Tsao, Li-Chung <br/><br/>
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.  [electronic resource] 

 -  JCI insight  12 2019 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>2379-3708 
<br/><br/><label>Standard No.: </label>10.1172/jci.insight.131882  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibody-Dependent Cell Cytotoxicity--drug effects<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Breast--pathology<br/>Breast Neoplasms--drug therapy<br/>CD47 Antigen--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Female<br/>Humans<br/>Immunity, Innate--drug effects<br/>Macrophages--drug effects<br/>Mice<br/>Phagocytosis--drug effects<br/>Prognosis<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Trastuzumab--pharmacology<br/>Xenograft Model Antitumor Assays